Metrics & Benchmarks

>

Latest News

Credit: Andrii | stock.adobe.com. Psoriatic Arthritis is shown using the text
Phase III POETYK PsA Trials Show Significant Clinical Benefit with Sotyktu in Psoriatic Arthritis

June 13th 2025

New data from the POETYK PsA-Phase III trial, presented at the 2025 EULAR Congress, demonstrate that Bristol Myers Squibb’s Sotyktu (deucravacitinib) significantly improves joint and skin symptoms in adults with active psoriatic arthritis, maintaining efficacy through 52 weeks of treatment.

Credit: and.one | stock.adobe.com. Elderly man suffering from psoriasis on hands
Phase IIIb APEX Trial Finds Tremfya Significantly Slows Joint Damage Progression in Psoriatic Arthritis

June 11th 2025

Credit: Dr_Microbe | stock.adobe.com. Lung cancer, medical concept, 3D illustration showing cancerous tumor inside human lung
Phase III DeLLphi-304 Trial Finds Imdelltra Significantly Extends Survival in Relapsed Small-Cell Lung Cancer

June 10th 2025

Credit: Crystal light | stock.adobe.com. Chronic kidney disease. 3d illustration
CONFIDENCE Trial Demonstrates Superior Outcomes With Kerendia and Jardiance Combination in CKD and T2D

June 9th 2025

Credit: Saiful52 | stock.adobe.com. Microscopic view of bone marrow slide feature are suggestive Multiple myeloma, also known as myeloma, is a type of bone marrow cancer.
Phase III IRAKLIA and Phase II IZALCO Trials Support Sarclisa On-Body Delivery for Relapsed/Refractory Multiple Myeloma

June 6th 2025

Video Interviews

More News

© 2025 MJH Life Sciences

All rights reserved.